Skip to Content
Merck
All Photos(1)

Key Documents

PHR1362

Supelco

Calcium Acetate

Pharmaceutical Secondary Standard; Certified Reference Material

Synonym(s):

Calcium acetate

Sign Into View Organizational & Contract Pricing


About This Item

Linear Formula:
(CH3CO2)2Ca
CAS Number:
Molecular Weight:
158.17
EC Number:
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24

grade

certified reference material
pharmaceutical secondary standard

Quality Level

Agency

traceable to USP 1086334

API family

calcium acetate

CofA

current certificate can be downloaded

technique(s)

HPLC: suitable
gas chromatography (GC): suitable

impurities

~1% Acetic acid

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-30°C

SMILES string

CC(=O)O[Ca]OC(C)=O

InChI

1S/2C2H4O2.Ca/c2*1-2(3)4;/h2*1H3,(H,3,4);/q;;+2/p-2

InChI key

VSGNNIFQASZAOI-UHFFFAOYSA-L

Looking for similar products? Visit Product Comparison Guide

General description

Calcium Acetate belongs to the group of calcium salts, widely used as phosphorus binders in patients with chronic renal failure.
Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.

Application

These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.

Footnote

To see an example of a Certificate of Analysis for this material enter LRAA1466 in the slot below. This is an example certificate only and may not be the lot that you receive.

related product

Storage Class Code

11 - Combustible Solids

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Mahmut Ilker Yilmaz et al.
American journal of kidney diseases : the official journal of the National Kidney Foundation, 59(2), 177-185 (2011-12-06)
Fibroblast growth factor 23 (FGF-23) is a marker of endothelial dysfunction and atherosclerotic complications in patients with chronic kidney disease (CKD). Because previous studies suggested that sevelamer may exert effects on FGF-23 level and endothelial function independently of its phosphate-lowering
Adrian Covic et al.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 28(9), 2383-2392 (2013-06-22)
Different phosphate binders exert differing effects on bone mineral metabolism and levels of regulating hormones. The objective of this post hoc evaluation of the CALcium acetate MAGnesium carbonate (CALMAG) study was to compare the effects of calcium acetate/magnesium carbonate (CaMg)
Melanie Gorman Ng et al.
The Annals of occupational hygiene, 57(5), 627-639 (2013-01-15)
Although dustiness and viscosity are potential determinants of dermal exposure, their effect on exposure is poorly understood. The goal of this study was to investigate the effect of dustiness and viscosity on dermal exposure by each of three dermal exposure
Leonardo V Riella et al.
American journal of kidney diseases : the official journal of the National Kidney Foundation, 57(4), 641-645 (2011-02-22)
Hypophosphatemia is a common complication after kidney transplant, affecting >90% of patients. However, no specific recommendations for phosphate repletion exist for transplant recipients. We report a case of a 70-year-old highly sensitized woman with end-stage renal disease caused by diabetic
Daniel T Grima et al.
Current medical research and opinion, 29(2), 109-115 (2012-12-12)
The avoidance of hospitalizations and the maintenance of in-center dialysis sessions in patients receiving dialysis for end-stage renal disease (ESRD) have obvious benefits to patients, dialysis providers and payers. Benefits include better continuity of care, better patient outcomes, improved quality

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service